196 related articles for article (PubMed ID: 29371340)
1. The Utility of Urinalysis in Determining the Risk of Renal Relapse in ANCA-Associated Vasculitis.
Rhee RL; Davis JC; Ding L; Fervenza FC; Hoffman GS; Kallenberg CGM; Langford CA; McCune WJ; Monach PA; Seo P; Spiera R; St Clair EW; Specks U; Stone JH; Merkel PA
Clin J Am Soc Nephrol; 2018 Feb; 13(2):251-257. PubMed ID: 29371340
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Value of Microscopic Hematuria after Induction of Remission in Antineutrophil Cytoplasmic Antibodies-Associated Vasculitis.
Vandenbussche C; Bitton L; Bataille P; Glowacki F; Azar R; Hatron PY; Macnamara E; Gheerbrant JD; Cardon G; Hoffmann M; Auxenfants E; Gnemmi V; Quéméneur T
Am J Nephrol; 2019; 49(6):479-486. PubMed ID: 31117066
[TBL] [Abstract][Full Text] [Related]
3. Proteinuria and hematuria after remission induction are associated with outcome in ANCA-associated vasculitis.
Benichou N; Charles P; Terrier B; Jones RB; Hiemstra T; Mouthon L; Bajema I; Berden A; Thervet E; Guillevin L; Jayne D; Karras A;
Kidney Int; 2023 Jun; 103(6):1144-1155. PubMed ID: 36940799
[TBL] [Abstract][Full Text] [Related]
4. ANCA-associated pauci-immune glomerulonephritis: always pauci-immune?
Scaglioni V; Scolnik M; Catoggio LJ; Christiansen SB; Varela CF; Greloni G; Rosa-Diez G; Soriano ER
Clin Exp Rheumatol; 2017; 35 Suppl 103(1):55-58. PubMed ID: 28229825
[TBL] [Abstract][Full Text] [Related]
5. Clinico-pathological features and outcomes of patients with propylthiouracil-associated ANCA vasculitis with renal involvement.
Chen Y; Bao H; Liu Z; Zhang H; Zeng C; Liu Z; Hu W
J Nephrol; 2014 Apr; 27(2):159-64. PubMed ID: 24570072
[TBL] [Abstract][Full Text] [Related]
6. Sequential Therapy for Remission Induction in Severe Antineutrophil Cytoplasmic Autoantibody-Associated Glomerulonephritis.
Kant S; Habbach A; Gapud EJ; Manno RL; Gattu R; Seo P; Geetha D
Am J Nephrol; 2019; 50(5):386-391. PubMed ID: 31593967
[TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides.
Terrier B; Pagnoux C; Perrodeau É; Karras A; Khouatra C; Aumaître O; Cohen P; Decaux O; Desmurs-Clavel H; Maurier F; Gobert P; Quémeneur T; Blanchard-Delaunay C; Bonnotte B; Carron PL; Daugas E; Ducret M; Godmer P; Hamidou M; Lidove O; Limal N; Puéchal X; Mouthon L; Ravaud P; Guillevin L;
Ann Rheum Dis; 2018 Aug; 77(8):1150-1156. PubMed ID: 29724729
[TBL] [Abstract][Full Text] [Related]
8. Rituximab for treatment of severe renal disease in ANCA associated vasculitis.
Geetha D; Hruskova Z; Segelmark M; Hogan J; Morgan MD; Cavero T; Eriksson P; Seo P; Manno RL; Dale J; Harper L; Tesar V; Jayne DR
J Nephrol; 2016 Apr; 29(2):195-201. PubMed ID: 25986390
[TBL] [Abstract][Full Text] [Related]
9. Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement.
Geetha D; Specks U; Stone JH; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Fessler BJ; Ding L; Tchao NK; Ikle D; Jepson B; Brunetta P; Fervenza FC;
J Am Soc Nephrol; 2015 Apr; 26(4):976-85. PubMed ID: 25381429
[TBL] [Abstract][Full Text] [Related]
10. Persistent hematuria in patients with antineutrophil cytoplasmic antibody-associated vasculitis during clinical remission: chronic glomerular lesion or low-grade active renal vasculitis?
Lv L; Chang DY; Li ZY; Chen M; Hu Z; Zhao MH
BMC Nephrol; 2017 Dec; 18(1):354. PubMed ID: 29207950
[TBL] [Abstract][Full Text] [Related]
11. Increase of Antimyeloperoxidase Antineutrophil Cytoplasmic Antibody (ANCA) in Patients with Renal ANCA-associated Vasculitis: Association with Risk to Relapse.
Yamaguchi M; Ando M; Kato S; Katsuno T; Kato N; Kosugi T; Sato W; Tsuboi N; Yasuda Y; Mizuno M; Ito Y; Matsuo S; Maruyama S
J Rheumatol; 2015 Oct; 42(10):1853-60. PubMed ID: 26373560
[TBL] [Abstract][Full Text] [Related]
12. Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: A randomised trial.
Maritati F; Alberici F; Oliva E; Urban ML; Palmisano A; Santarsia F; Andrulli S; Pavone L; Pesci A; Grasselli C; Santi R; Tumiati B; Manenti L; Buzio C; Vaglio A
PLoS One; 2017; 12(10):e0185880. PubMed ID: 29016646
[TBL] [Abstract][Full Text] [Related]
13. Long term azathioprine maintenance therapy in ANCA-associated vasculitis: combined results of long-term follow-up data.
de Joode AAE; Sanders JSF; Puéchal X; Guillevin LP; Hiemstra TF; Flossmann O; Rasmussen N; Westman K; Jayne DR; Stegeman CA
Rheumatology (Oxford); 2017 Nov; 56(11):1894-1901. PubMed ID: 28977502
[TBL] [Abstract][Full Text] [Related]
14. Plasma exchange and glucocorticoids to delay death or end-stage renal disease in anti-neutrophil cytoplasm antibody-associated vasculitis: PEXIVAS non-inferiority factorial RCT.
Jayne D; Walsh M; Merkel PA; Peh CA; Szpirt W; Puéchal X; Fujimoto S; Hawley C; Khalidi N; Jones R; Flossmann O; Wald R; Girard L; Levin A; Gregorini G; Harper L; Clark W; Pagnoux C; Specks U; Smyth L; Ito-Ihara T; de Zoysa J; Brezina B; Mazzetti A; McAlear CA; Reidlinger D; Mehta S; Ives N; Brettell EA; Jarrett H; Wheatley K; Broadhurst E; Casian A; Pusey CD
Health Technol Assess; 2022 Sep; 26(38):1-60. PubMed ID: 36155131
[TBL] [Abstract][Full Text] [Related]
15. Anti-cytokine targeted therapies for ANCA-associated vasculitis.
Bala MM; Malecka-Massalska TJ; Koperny M; Zajac JF; Jarczewski JD; Szczeklik W
Cochrane Database Syst Rev; 2020 Sep; 9(9):CD008333. PubMed ID: 32990324
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study.
Jayne D; Blockmans D; Luqmani R; Moiseev S; Ji B; Green Y; Hall L; Roth D; Henderson RB; Merkel PA;
Arthritis Rheumatol; 2019 Jun; 71(6):952-963. PubMed ID: 30666823
[TBL] [Abstract][Full Text] [Related]
17. ANCA-associated vasculitis in scleroderma: A renal perspective
.
Kant S; Shah AA; Hummers LK; Wigley FM; Geetha D
Clin Nephrol; 2018 Dec; 90(6):413-418. PubMed ID: 30106367
[TBL] [Abstract][Full Text] [Related]
18. urinary biomarkers in relapsing antineutrophil cytoplasmic antibody-associated vasculitis.
Lieberthal JG; Cuthbertson D; Carette S; Hoffman GS; Khalidi NA; Koening CL; Langford CA; Maksimowicz-McKinnon K; Seo P; Specks U; Ytterberg SR; Merkel PA; Monach PA;
J Rheumatol; 2013 May; 40(5):674-83. PubMed ID: 23547217
[TBL] [Abstract][Full Text] [Related]
19. Negative anti-neutrophil cytoplasm antibody at switch to maintenance therapy is associated with a reduced risk of relapse.
Morgan MD; Szeto M; Walsh M; Jayne D; Westman K; Rasmussen N; Hiemstra TF; Flossmann O; Berden A; Höglund P; Harper L;
Arthritis Res Ther; 2017 Jun; 19(1):129. PubMed ID: 28592297
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of remission induction therapy for ANCA-associated vasculitis in the elderly.
Aqeel F; Xu L; Salas A; Wen Y; Eid SM; Geetha D
Clin Rheumatol; 2023 Sep; 42(9):2427-2435. PubMed ID: 37225927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
